Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask The Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
PR Newswire
Report Store
UsernamePublicRestriction
Tags:
Medical Device

BDSI buys US rights to BEMA (bioerodible mucoadhesive disc) drug tech

This article was originally published in Clinica

  • News

Executive Summary

BioDelivery Sciences International (BDSI) has acquired the US rights to the BEMA (bioerodible mucoadhesive disc) drug delivery technology developed by biopharmaceutical company QLT for $3m. BDSI has also agreed to pay QLT up to $4m for achieving certain milestones, one of these being the NDA approval of BDSI's first BEMA product.

Table

View full table

Advertisement
Advertisement

Topics

Advertisement
Tags:
Medical Device
UsernamePublicRestriction

Register

MT049741

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By